• Japanese
  • Korean
  • Chinese
Cover Image

Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

Executive Summary

Tailor-Made Treatments in Oncology to Dominate Future Therapy.

Cancer treatments are becoming increasingly personalized, as regulators are approving therapeutics offering significant benefits to small target populations, according to a new report by healthcare experts GBI Research.

The new report* states that although therapeutic options that target a small population are expensive, their uptake is expected to be rapid in the target population.

The approval of Pfizer's Xalkori (crizotinib), which treats only 5% of the total Non-Small Cell Lung Cancer (NSCLC) patient population, and the change in Erbitux's coverage of the colorectal cancer patient population (from every patient to wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) patients) indicates a shift in focus to more personalized cancer treatment.

The launch of novel pipeline molecules such as Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM, is projected to add $2,979m in revenue by 2018. These novel molecules are expected to be launched during the next six years, and are expected to increase progression-free survival, therefore promising a better life to many cancer patients. The molecules are also expected to address the safety and unmet needs of various cancer treatments for breast cancer, ovarian cancer, cervical cancer, NSCLC and Non-Hodgkin's Lymphoma (NHL).

The development pipeline contains targeted therapeutics in Phase III, which are expected to be launched during the next few years to drive growth in the oncology market. Pipeline drugs include protein kinase inhibitors, monoclonal antibodies and vaccines, with a total of 1,198 molecules under investigation.

The protein kinase inhibitor has the highest number of molecules under development, accounting for 42% of the oncology pipeline, with 194 monoclonal antibody molecules in development and 63 vaccine molecules in various stages of development. Protein kinase inhibitors are one of the major classes under development, due to the role of this protein in helping cancer cells evade normal physiological constraints on growth and survival.

Monoclonal antibodies such as Avastin (bevacizumab), Erbitux (cetuximab), Rituxan (rituximab) and Herceptin (trastuzumab) also represent a leading class of drugs in the oncology therapeutics market. These are safer and more effective than the conventional chemotherapy treatment options, and target the unmet needs of late-stage cancer patients, having proven successful in improving survival and quality of life. The number of monoclonal antibodies in the drug development pipeline for the treatment of cancer increased over the last decade, driven by their own success, but they are therefore priced at a premium.

GBI Research predicts that novel therapies will generate revenue of $2,979m by 2018 for the oncology therapeutics market, which will grow at a CAGR of 113% during 2012-2018.

Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

This report provides in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Abstract

Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline" which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

GBI Research also analyzed the promising pipeline molecules that are expected to be launched during the forecast period (2012-2018). The molecules are Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM. The launch of promising molecules is projected to add $2,979m in revenues by 2018. The novel molecules are expected to increase progression free survival, providing a better treatment option to cancer patients. The molecules are expected to address the safety and unmet needs. GBI Research analyzed 63 M&A deals, 95 licensing deals and 67 R&D collaboration agreements that took place during 2007-2011 and found that competitive activity is increasing in the oncology therapeutics market.

Scope

  • Data and analysis on the leading therapeutic classes in oncology.
  • Market data on the promising molecules in the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer.
  • Key M&A activities and licensing agreements that took place from 2005-2011 in the oncology market.

Reasons to buy

  • Align your product portfolio to markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

TOC

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 9
  • 1.2 List of Figures 12

2 Novel Therapies in Oncology - Introduction 15

3 Novel Therapies in Oncology - Key Innovations and Technologies 16

  • 3.1 Introduction 16
    • 3.1.1 Increase in Cancer 17
    • 3.1.2 Risk Factors for Cancer 17
  • 3.2 Oncology Treatment Pathways 17
    • 3.2.1 Chemotherapeutics 17
    • 3.2.2 Targeted Therapies 18
  • 3.3 Leading Marketed Drugs in Oncology 18
    • 3.3.1 Rituxan/ MabThera 18
    • 3.3.2 Herceptin 19
    • 3.3.3 Gleevec/Glivec 20
    • 3.3.4 Avastin 21
    • 3.3.5 Eloxatin 21
    • 3.3.6 Erbitux 22
    • 3.3.7 Xeloda 22
    • 3.3.8 Femara 23
    • 3.3.9 Temodar 23
    • 3.3.10 Tarceva 24
    • 3.3.11 Taxotere 25
    • 3.3.12 Revlimid 25
    • 3.3.13 Alimta 26

4 Novel Therapies in Oncology - Leading Novel Drug Classes for the Future 27

  • 4.1 Protein Kinase Inhibitors 27
  • 4.2 Vaccines 28
    • 4.2.1 Tumor Cell Vaccines 29
    • 4.2.2 Antigen Vaccines 29
    • 4.2.3 Dendritic Cell Vaccines 30
    • 4.2.4 Anti-Idiotype vaccines 30

5 Novel Therapies in Oncology - Opportunity and Unmet Need Analysis 31

  • 5.1 Breast Cancer 31
  • 5.2 Colorectal Cancer 33
  • 5.3 NHL 34
  • 5.4 NSCLC 36
  • 5.5 Prostate Cancer 38
  • 5.6 Ovarian Cancer 39
  • 5.7 Cervical Cancer 40
  • 5.8 Head and Neck Cancer 41

6 Novel Therapies in Oncology - Product Pipeline Analysis 43

  • 6.1 Introduction 43
  • 6.2 Breast Cancer 47
    • 6.2.1 Breast Cancer Pipeline - Introduction 47
    • 6.2.2 Breast Cancer Pipeline - Analysis by Therapeutic Class 48
    • 6.2.3 Breast Cancer Pipeline - Pre-Clinical 53
    • 6.2.4 Breast Cancer Pipeline - Discovery 54
    • 6.2.5 Breast Cancer Pipeline - Phase I 55
    • 6.2.6 Breast Cancer Pipeline - Phase II 57
    • 6.2.7 Breast Cancer Pipeline - Phase III 61
    • 6.2.8 Breast Cancer Pipeline - NDA Filed 61
  • 6.3 Colorectal Cancer 62
    • 6.3.1 Colorectal Cancer Pipeline - Introduction 62
    • 6.3.2 Colorectal Cancer Pipeline - Analysis by Therapeutic Class 63
    • 6.3.3 Colorectal Cancer Pipeline - Pre-Clinical 68
    • 6.3.4 Colorectal Cancer Pipeline - Discovery 68
    • 6.3.5 Colorectal Cancer Pipeline - Phase I 69
    • 6.3.6 Colorectal Cancer Pipeline - Phase II 71
    • 6.3.7 Colorectal Cancer Pipeline - Phase III 74
  • 6.4 NHL 75
    • 6.4.1 NHL Pipeline - Introduction 75
    • 6.4.2 NHL Pipeline - Analysis by Therapeutic Class 76
    • 6.4.3 NHL Pipeline - Pre-Clinical 81
    • 6.4.4 NHL Pipeline - Discovery 81
    • 6.4.5 NHL Pipeline - Phase I 82
    • 6.4.6 NHL Pipeline - Phase II 84
    • 6.4.7 NHL Pipeline - Phase III 85
    • 6.4.8 NHL Pipeline - NDA Filed 85
  • 6.5 NSCLC 86
    • 6.5.1 NSCLC Pipeline - Introduction 86
    • 6.5.2 NSCLC Pipeline - Analysis by Therapeutic Class 87
    • 6.5.3 NSCLC Pipeline - Pre-Clinical 93
    • 6.5.4 NSCLC Pipeline - Discovery 94
    • 6.5.5 NSCLC Pipeline - Phase I 94
    • 6.5.6 NSCLC Pipeline - Phase II 95
    • 6.5.7 NSCLC Pipeline - Phase III 97
    • 6.5.8 NSCLC Pipeline - NDA Filed 98
  • 6.6 Prostate Cancer 99
    • 6.6.1 Prostate Cancer Pipeline - Introduction 99
    • 6.6.2 Prostate Cancer Pipeline - Analysis by Therapeutic Class 100
    • 6.6.3 Prostate Cancer Pipeline - Pre-Clinical 106
    • 6.6.4 Prostate Cancer Pipeline - Discovery 107
    • 6.6.5 Prostate Cancer Pipeline - Phase I 108
    • 6.6.6 Prostate Cancer Pipeline - Phase II 109
    • 6.6.7 Prostate Cancer Pipeline - Phase III 111
    • 6.6.8 Prostate Cancer Pipeline - NDA Filed 112
  • 6.7 Ovarian Cancer 112
    • 6.7.1 Ovarian Cancer Pipeline - Introduction 112
    • 6.7.2 Ovarian Cancer Pipeline - Analysis by Therapeutic Class 113
    • 6.7.3 Ovarian Cancer Pipeline - Pre-Clinical 117
    • 6.7.4 Ovarian Cancer Pipeline - Discovery 118
    • 6.7.5 Ovarian Cancer Pipeline - Phase I 119
    • 6.7.6 Ovarian Cancer Pipeline - Phase II 120
    • 6.7.7 Ovarian Cancer Pipeline - Phase III 122
    • 6.7.8 Ovarian Cancer Pipeline - NDA Filed 122
  • 6.8 Cervical Cancer 123
    • 6.8.1 Cervical Cancer Pipeline - Introduction 123
    • 6.8.2 Cervical Cancer Pipeline - Analysis by Therapeutic Class 124
    • 6.8.3 Cervical Cancer Pipeline - Pre-Clinical 128
    • 6.8.4 Cervical Cancer Pipeline - Phase I 128
    • 6.8.5 Cervical Cancer Pipeline - Phase II 129
    • 6.8.6 Cervical Cancer Pipeline - Phase III 129
  • 6.9 Head and Neck Cancer 130
    • 6.9.1 Head and Neck Cancer Pipeline - Introduction 130
    • 6.9.2 Head and Neck Cancer Pipeline - Analysis by Therapeutic Class 131
    • 6.9.3 Head and Neck Cancer Pipeline - Pre-Clinical 135
    • 6.9.4 Head and Neck Cancer Pipeline - Discovery 135
    • 6.9.5 Head and Neck Cancer Pipeline - Phase I 136
    • 6.9.6 Head and Neck Cancer Pipeline - Phase II 137
    • 6.9.7 Head and Neck Cancer Pipeline - Phase III 139

7 Novel Therapies In Oncology - Promising Molecules 140

  • 7.1 T-DM1 140
    • 7.1.1 Introduction 140
    • 7.1.2 Mechanism of Action 140
    • 7.1.3 Revenues 140
  • 7.2 Afinitor (everolimus) 141
    • 7.2.1 Introduction 141
    • 7.2.2 Mechanism of Action 141
    • 7.2.3 Revenues 142
  • 7.3 Iniparib (E75) 143
    • 7.3.1 Introduction 143
    • 7.3.2 Mechanism of Action 143
    • 7.3.3 Revenues 144
  • 7.4 Afatinib 145
    • 7.4.1 Introduction 145
    • 7.4.2 Mechanism of Action 145
    • 7.4.3 Revenues 145
  • 7.5 Avastin 146
    • 7.5.1 Introduction 146
    • 7.5.2 Mechanism of Action 146
    • 7.5.3 Revenues 146
  • 7.6 Farletuzumab 147
    • 7.6.1 Introduction 147
    • 7.6.2 Mechanism of Action 147
    • 7.6.3 Revenues 148
  • 7.7 V503 149
    • 7.7.1 Introduction 149
    • 7.7.2 Mechanism of Action 149
    • 7.7.3 Revenues 149
  • 7.8 Tykerb 150
    • 7.8.1 Introduction 150
    • 7.8.2 Mechanism of Action 150
    • 7.8.3 Revenues 151
  • 7.9 TheraCIM 152
    • 7.9.1 Introduction 152
    • 7.9.2 Mechanism of Action 152
    • 7.9.3 Revenues 153

8 Novel Therapies In Oncology - Strategic Consolidations 154

  • 8.1 M&A Landscape 154
    • 8.1.1 M&A Deals by Year 156
    • 8.1.2 M&A Deals by Geography 157
    • 8.1.3 M&A Deals by Value 158
    • 8.1.4 M&A Deals by Deal Type 159
  • 8.2 R&D Licensing Agreements 160
    • 8.2.1 Deals by Year 161
    • 8.2.2 Deals by Geography 162
    • 8.2.3 Deals by Value 163
  • 8.3 Co-Development Agreements 164
    • 8.3.1 Deals by Year 165
    • 8.3.2 Deals by Geography 166
    • 8.3.3 Deals by Value 167

9 Novel Therapies In Oncology - Appendix 168

  • 9.1 Market Definitions 168
  • 9.2 Abbreviations 168
  • 9.3 Sources 169
  • 9.4 Research Methodology 170
    • 9.4.1 Coverage 170
    • 9.4.2 Secondary Research 170
    • 9.4.3 Primary Research 171
    • 9.4.4 Section Wise Methodology 171
    • 9.4.5 Expert Panel Validation 171
  • 9.5 Contact Us 172
  • 9.6 Disclaimer 172

List of Tables

1.1 List of Tables

  • Table 1: Novel Therapies in Oncology, Oncology Clinical Trials, 2011 16
  • Table 2: Novel Therapies in Oncology, Pipeline by Developmental Phase, 2011 43
  • Table 3: Novel Therapies in Oncology, Pipeline by Indication, 2011 45
  • Table 4: Novel Therapies in Oncology, Pipeline by Therapeutic Class, 2011 46
  • Table 5: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase, 2011 47
  • Table 6: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 48
  • Table 7: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 49
  • Table 8: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 50
  • Table 9: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 51
  • Table 10: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 52
  • Table 11: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 53
  • Table 12: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Stage Molecules, 2011 54
  • Table 13: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules, 2011 55
  • Table 14: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules, 2011 57
  • Table 15: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules, 2011 61
  • Table 16: Novel Therapies in Oncology, Breast Cancer Pipeline, NDA Filed Molecules, 2011 61
  • Table 17: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase, 2011 62
  • Table 18: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 63
  • Table 19: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 64
  • Table 20: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class , 2011 65
  • Table 21: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 66
  • Table 22: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 67
  • Table 23: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 68
  • Table 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Stage Molecules, 2011 68
  • Table 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules, 2011 69
  • Table 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules, 2011 71
  • Table 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules, 2011 74
  • Table 28: Novel Therapies in Oncology, NHL Pipeline by Phase, 2011 75
  • Table 29: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 76
  • Table 30: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class, 2011 77
  • Table 31: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class, 2011 78
  • Table 32: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class, 2011 79
  • Table 33: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class, 2011 80
  • Table 34: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Stage Molecules, 2011 81
  • Table 35: Novel Therapies in Oncology, NHL Pipeline, Discovery Stage Molecules, 2011 81
  • Table 36: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules, 2011 82
  • Table 37: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules, 2011 84
  • Table 38: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules, 2011 85
  • Table 39: Novel Therapies in Oncology, NHL Pipeline, NDA Filed Molecules, 2011 85
  • Table 40: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase, 2011 86
  • Table 41: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 87
  • Table 42: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class, 2011 88
  • Table 43: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class, 2011 89
  • Table 44: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class, 2011 90
  • Table 45: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class, 2011 91
  • Table 46: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class, 2011 92
  • Table 47: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Stage Molecules, 2011 93
  • Table 48: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Stage Molecules, 2011 94
  • Table 49: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules, 2011 94
  • Table 50: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules, 2011 95
  • Table 51: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules, 2011 97
  • Table 52: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules, 2011 98
  • Table 53: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase, 2011 99
  • Table 54: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 101
  • Table 55: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 102
  • Table 56: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 103
  • Table 57: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 104
  • Table 58: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class, 2011 105
  • Table 59: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 106
  • Table 60: Novel Therapies in Oncology, Prostate Cancer Pipeline, Discovery Stage Molecules, 2011 107
  • Table 61: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules, 2011 108
  • Table 62: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules, 2011 109
  • Table 63: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules, 2011 111
  • Table 64: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules, 2011 112
  • Table 65: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase, 2011 112
  • Table 66: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 113
  • Table 67: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class,2011 114
  • Table 68: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 115
  • Table 69: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 116
  • Table 70: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 117
  • Table 71: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Discovery Stage Molecules, 2011 118
  • Table 72: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules, 2011 119
  • Table 73: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules, 2011 120
  • Table 74: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 122
  • Table 75: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011 122
  • Table 76: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase, 2011 123
  • Table 77: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 124
  • Table 78: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 125
  • Table 79: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 126
  • Table 80: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 127
  • Table 81: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 128
  • Table 82: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules, 2011 128
  • Table 83: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules, 2011 129
  • Table 84: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules, 2011 129
  • Table 85: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase, 2011 130
  • Table 86: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011 131
  • Table 87: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011 131
  • Table 88: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011 132
  • Table 89: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011 133
  • Table 90: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011 134
  • Table 91: Novel Therapies in Oncology, Head And Neck Cancer Pipeline, Pre-Clinical Stage Molecules, 2011 135
  • Table 92: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Stage Molecules, 2011 135
  • Table 93: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules, 2011 136
  • Table 94: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules, 2011 137
  • Table 95: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules, 2011 139
  • Table 96: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018 140
  • Table 97: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018 142
  • Table 98: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018 144
  • Table 99: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018 145
  • Table 100: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018 147
  • Table 101: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2015-2018 148
  • Table 102: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018 149
  • Table 103: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018 151
  • Table 104: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018 153
  • Table 105: Novel Therapies in Oncology, Global, Major M&A Deals, 2007-2011 154
  • Table 106: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011 156
  • Table 107: Novel Therapies in Oncology, Global, M&A Deals by Geography, 2007-2011 157
  • Table 108: Novel Therapies in Oncology, Global, M&A Deals by Value, 2007-2011 158
  • Table 109: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, 2007-2011 159
  • Table 110: Novel Therapies in Oncology, Global, Major R&D Licensing Deals, 2007-2011 160
  • Table 111: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011 161
  • Table 112: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, 2007-2011 162
  • Table 113: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, 2007-2011 163
  • Table 114: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 164
  • Table 115: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 165
  • Table 116: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, 2007-2011 166
  • Table 117: Novel Therapies in Oncology, Global, Co-Development Deals by Value, 2007-2011 167

List of Figures

1.2 List of Figures

  • Figure 1: Novel Therapies in Oncology, Oncology Clinical Trials Share (%), 2011 16
  • Figure 2: Novel Therapies in Oncology, Protein Kinase Inhibitors Molecules by Indication, 2011 27
  • Figure 3: Novel Therapies in Oncology, Vaccine Molecules by Indication, 2011 28
  • Figure 4: Novel Therapies in Oncology, Metastatic Breast Cancer Opportunity and Unmet Need Analysis, 2011 31
  • Figure 5: Novel Therapies in Oncology, Adjuvant Breast Cancer Opportunity and Unmet Need Analysis, 2011 32
  • Figure 6: Novel Therapies in Oncology, Colorectal Cancer Opportunity and Unmet Need Analysis, 2011 33
  • Figure 7: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, First-line Therapy, 2011 34
  • Figure 8: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, Second line Therapy, 2011 35
  • Figure 9: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, First line Therapy, 2011 36
  • Figure 10: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, Second Line Therapy, 2011 37
  • Figure 11: Novel Therapies in Oncology, Prostate Cancer Opportunity and Unmet Need Analysis, 2011 38
  • Figure 12: Novel Therapies in Oncology, Ovarian Cancer Opportunity and Unmet Need Analysis, 2011 39
  • Figure 13: Novel Therapies in Oncology, Cervical Cancer Opportunity and Unmet Need Analysis, 2011 40
  • Figure 14: Novel Therapies in Oncology, Head and Neck Cancer Opportunity and Unmet Need Analysis, 2011 41
  • Figure 15: Novel Therapies in Oncology, Pipeline by Developmental Phase (%), 2011 43
  • Figure 16: Novel Therapies in Oncology, Pipeline by Indication (%), 2011 44
  • Figure 17: Novel Therapies in Oncology, Pipeline by Therapeutic Class (%), 2011 45
  • Figure 18: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase (%), 2011 47
  • Figure 19: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 48
  • Figure 20: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 49
  • Figure 21: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 50
  • Figure 22: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 51
  • Figure 23: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 52
  • Figure 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase (%), 2011 62
  • Figure 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 63
  • Figure 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 64
  • Figure 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 65
  • Figure 28: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 66
  • Figure 29: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 67
  • Figure 30: Novel Therapies in Oncology, NHL Pipeline by Phase (%), 2011 75
  • Figure 31: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 76
  • Figure 32: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 77
  • Figure 33: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 78
  • Figure 34: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 79
  • Figure 35: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 80
  • Figure 36: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase (%), 2011 86
  • Figure 37: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 87
  • Figure 38: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class (%), 2011 88
  • Figure 39: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 89
  • Figure 40: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 90
  • Figure 41: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 91
  • Figure 42: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011 92
  • Figure 43: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase (%), 2011 99
  • Figure 44: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 100
  • Figure 45: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 102
  • Figure 46: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 103
  • Figure 47: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 104
  • Figure 48: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011 105
  • Figure 49: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase (%), 2011 112
  • Figure 50: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 113
  • Figure 51: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 114
  • Figure 52: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 115
  • Figure 53: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 116
  • Figure 54: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase (%), 2011 123
  • Figure 55: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 124
  • Figure 56: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 125
  • Figure 57: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 126
  • Figure 58: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 127
  • Figure 59: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase (%), 2011 130
  • Figure 60: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011 131
  • Figure 61: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011 132
  • Figure 62: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011 133
  • Figure 63: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011 134
  • Figure 64: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018 140
  • Figure 65: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018 142
  • Figure 66: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018 144
  • Figure 67: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018 145
  • Figure 68: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018 146
  • Figure 69: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2014-2018 148
  • Figure 70: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018 149
  • Figure 71: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018 151
  • Figure 72: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018 153
  • Figure 73: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011 156
  • Figure 74: Novel Therapies in Oncology, Global, M&A Deals by Geography, (%), 2007-2011 157
  • Figure 75: Novel Therapies in Oncology, Global, M&A Deals by Value, (%), 2007-2011 158
  • Figure 76: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, (%), 2007-2011 159
  • Figure 77: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011 161
  • Figure 78: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, (%), 2007-2011 162
  • Figure 79: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, (%), 2007-2011 163
  • Figure 80: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011 165
  • Figure 81: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, (%), 2007-2011 166
  • Figure 82: Novel Therapies in Oncology, Global, Co-Development Deals by Value, (%), 2007-2011 167
Show More
Pricing
Get Notified
Email me when related reports are published